6533b826fe1ef96bd1284f1e

RESEARCH PRODUCT

Dupilimab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Asthma by Body Mass Index

Ariel TeperHeribert StaudingerMarcella RuddyNeil M.h. GrahamPaul RoweWilliam W. BusseMegan S. RiceJanos MucsiAnne E. DixonJose Echave-sustaetaNikhil AminYamo DenizStephanie Korn

subject

Moderate to severemedicine.medical_specialtybusiness.industryInterleukinmacromolecular substancesmedicine.diseasePlaceboObesityGastroenterologyDupilumabInternal medicinemedicineIn patientbusinessBody mass indexAsthma

description

Introduction: Obesity is associated with increased asthma severity, poor asthma control, and poor response to inhaled corticosteroids. Dupilumab (DPL), a fully human monoclonal antibody blocks the shared receptor component for interleukin (IL)-4/IL-13, key drivers of type 2 inflammation. In the phase 3 QUEST trial (NCT02414854), add-on DPL 200/300 mg every 2 wks (q2w) vs placebo (PBO) reduced severe exacerbations and improved pre-bronchodilator (BD) FEV1 in patients (pts) with uncontrolled, moderate-to-severe asthma. Aim: To assess the effect of baseline (BL) body mass index (BMI) on DPL efficacy in uncontrolled, moderate-to-severe asthma pts. Methods: Annualized rate of severe exacerbations during the 52-wk treatment period and LS mean (LSM) change from BL at Wk 12 in pre-BD FEV1 were assessed by BL BMI subgroups ( Results: Across all BL BMI subgroups, both DPL 200 and 300 mg q2w vs PBO consistently reduced severe exacerbations (–35.1 to –51.4%; all P Conclusion: Dupilumab reduced severe exacerbations and improved FEV1 in pts with uncontrolled, moderate-to-severe asthma, regardless of BL BMI or DPL dose received.

yearjournalcountryeditionlanguage
2019-09-28Allergy and immunology
https://doi.org/10.1183/13993003.congress-2019.pa2753